

# Harmonization on PBPK platform and model qualification for regulatory assessment

Viera Lukacova (Simulations Plus, Inc., Chief Scientific Officer)

# Agenda

- PBPK platform validation/qualification vs model validation/qualification
- Role of PBPK platform developers and sponsors in the validation/qualification process
- PBPK model validation/qualification within a risk assessment framework for specific applications
- Harmonization of PBPK model use in regulatory decision-making
- Reporting standards for PBPK analyses

# Platform Qualification

- **System parameters:**

- System/physiological parameters critical for the context of use (CoU)
- Reasonable assumptions for unknown parameters
- Case studies and publications outside of CoU can be used to support the system parameters


- **Equations:**

- Correct equations are implemented – platform documentation
- Equations are implemented correctly
  - Rewriting the equations in a different format (e.g., Matlab) does not answer this question
  - Could sensitivity analysis with artificial data (known outcomes) be a more relevant test/confirmation?

# Qualifying PBPK Platform for DDI

Accurate prediction of DDI for a series of selected substrates and perpetrators of different strengths (one enzyme or different enzymes) qualifies Platform - confirms that equations are correct and able to capture/predict the DDI


Emphasis should be placed on **diverse** (where applicable) rather than large validation dataset



# Qualifying Additional PBPK Models for DDI


Additional models are simply expanding the library of qualified models for DDI Prediction

**for the same protein**



# Qualifying Additional PBPK Models for DDI




Additional models are simply expanding the library of qualified models for DDI Prediction  
**for other proteins**



New system parameters  
(if relevant) will need to  
be documented

# Model Validation

- Model includes ALL relevant mechanisms
- Model is sensitive to changes in relevant input parameters
- Model ADEQUATELY captures/predicts PK of the compound for reference scenario (e.g., compound alone for DDI predictions)
- Model has ability to predict effect in question, for example:
  - Captures known DDIs (to predict DDIs for new scenarios - other substrates, other dosing scenarios, administration routes, etc.)
  - Captures contributions of different elimination pathways (to predict DDIs)
  - Captures all relevant mechanisms (to predict PK in other populations – this would be linked with platform qualification for extrapolation to different populations)



# Roles and Responsibilities

- **Platform developer:**

- Sound science – equations and default system parameters
- Documentation and information allowing regulator to verify the equations and system parameters
- Standard models (and documentation) if relevant for a specific CoU (e.g., standard models for DDI predictions)
- Documentation updates and model updates/revalidation (as relevant) with platform version updates

- **User of the platform:**

- Model construction and validation for specific compound and CoU (i.e., ensure relevant mechanisms are included)
- Justification and validation of changes to default system parameters

# Qualifying Next Versions

- How to qualify the next software version:
  - Clearly describe the changes in the new version
  - Focus on requalifying only the parts of the program which have changed
    - Requalifying of the sections of the program that changed – rerun test cases to ensure that the modification resulted only in intended changes and improved predictions where applicable
    - Remaining sections of the program – rerun test cases to show that unintended changes were not introduced
- Qualifying updated compound models supplied with the software:
  - Describe the changes in the model and explain why the model was changed (i.e., more accurate values for input parameters became available, etc.)
  - Describe and demonstrate the performance of the updated compound model

# Model and Platform Validation/Qualification within Risk Assessment Framework

- **Model:** Use of part of observed data to calibrate model, then prediction of remaining observations with reasonable accuracy without modifying the model
  - Reasonable means a level of accuracy sufficient to make well-informed project decisions
    - Varies by development stage
    - Varies by impact of the model
  - Consider variability in compound's PK – model cannot give more accurate prediction than clinical study
- **Platform:** The same platform will be used in different stages of drug development and for applications with varying impacts
  - The more conservative criteria for level of accuracy need to be used
  - Still need to consider variability in PK of compounds used for qualification – different prediction errors may be applicable for different compounds in the platform qualification dataset

# Geography Does Not Change the Science

- Similar mechanisms were proposed by FDA and EMA
  - Platform qualification vs. fit-for-purpose model (possibly model master file)
- Harmonization of platform qualification requirements will increase use of these pathways
  - Harmonize requirements for platform qualification
  - Can the same report/documentation be accepted by multiple agencies?
  - Can we push the boundaries and accept qualification across agencies?

# Conclusions

- Platform and model qualification process has the potential to streamline and accelerate the review process for specific drug product applications, but cases are rare
- Possible reasons for slow uptake of the qualification process
  - Resource demanding process (even more so if different process and requirements apply across agencies)
  - Uncertainty about conditions/process and expectations
  - Uncertainty about expectations from individual reviewers

# Acknowledgments

Susie Zhang  
Sandra Suarez-Sharp  
Xavier Pepin  
John DiBella

# Thank you

[viera.lukacova@simulations-plus.com](mailto:viera.lukacova@simulations-plus.com)

